Article Text

PDF
A multicentre evaluation of an opioid patient–provider agreement
  1. Joseph V Pergolizzi1,
  2. Frederick A Curro2,
  3. Nanada Col3,4,
  4. Mary Papa Ghods5,
  5. Don Vena6,
  6. Robert Taylor1,
  7. Frederick Naftolin7,
  8. Jo Ann LeQuang1
  1. 1 NEMA Research, Inc., Naples, Florida, USA
  2. 2 Practioners Engaged in Applied Research and Learning (PEARL) Practice-Based Translation Network, New York University, New York, USA
  3. 3 Shared Decision Making Resources, Rockville, USA
  4. 4 FDA Safe Use Initiative Opioid PPA Working Group, Silver Spring, Maryland, USA
  5. 5 U.S. Food and Drug Administration, Silver Spring, Maryland, USA
  6. 6 Practitioners Engaged in Applied Research and Learning (PEARL) Practice Based Clinical Translation Network Coordinating Center, The Emmes Corporation, Rockville, Maryland, USA
  7. 7 Practitioners Engaged in Applied Research and Learning (PEARL) Practice Based Clinical Translational Network, New York, USA
  1. Correspondence to Jo Ann LeQuang, NEMA Research, Inc. 1216 N. Velasco Street, Suite J Angleton, TX 77515, USA; joann{at}leqmedical.com

Abstract

The role of the patient–provider agreement (PPA) is to set forth respective roles and responsibilities for opioid therapy with the goal of improving outcomes, reducing risks, and improving patient education. The Food and Drug Administration (FDA) Safe Use Initiative Opioid PPA Working Group convened to develop a PPA and test it for acceptability as an educational and shared decision-making tool in opioid therapy. This multicentre study evaluated the utility of the PPA, how readily patients understood it, its ability to educate patients in an unbiased way about opioid treatment and the feasibility of incorporating a PPA in clinical practice. A total of 117 patients and 14 providers at urban centres were included (mean patient age: 56 years) with 85% of patients treated for pain for >3 months. Most patients reported the PPA to be ‘somewhat helpful’ or ‘very helpful’ in deciding a course of treatment (96%) and ‘easy to understand’ (97%). Both patients and prescribers (89% and 92%, respectively) found the PPA was neutral in terms of presenting opioid therapy. Most centres found the PPA could be administered in ≤10 min and 72% of prescribers said this PPA could be readily incorporated into their practice. This PPA was perceived by both patients and prescribers as helpful in deciding a course of treatment and unbiased in terms of presentation of the risks and benefits of opioid therapy.

  • opioids
  • opioid abuse
  • pain management
  • patient-provider agreement

Statistics from Altmetric.com

Footnotes

  • Contributors JVP, FAC, NC, MPG, DV, RT and FN have made substantial contributions to the conception/design of the work, analysis and interpretation of the data. JALQ has made substantial contributions to the writing and editing of the manuscript and interpretation of the data. All authors contributed to the drafting and critical review of the work.

    JVP, FAC and MPG developed the prescriber agreement and planned the clinical study. JVP, FAC, NC, RT and FN executed the clinical study. FAC and DV conducted the data analysis. All authors contributed to the interpretation of the data. All authors contributed to the drafting and critical review of the manuscript/work.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.